Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 185,070	$ 376,976
Investments in marketable securities, current	154,112
Prepaid expenses and other current assets	4,574	4,760
Total current assets	343,756	381,736
Restricted cash, non-current	1,716	1,716
Investments in marketable securities, non-current	12,927
Property and equipment, net	9,374	6,507
Operating lease right-of-use assets	10,122	11,574
Other assets	711	454
Total assets	378,606	401,987
Current liabilities:
Accounts payable	3,069	2,453
Accrued compensation	1,023	2,689
Accrued research costs	1,879	633
Accrued expenses and other current liabilities	1,158	886
Operating lease liabilities, current	5,636	5,482
Total current liabilities	12,765	12,143
Operating lease liabilities, non-current	4,542	5,794
Total liabilities	17,307	17,937
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.00001 par value, 10,000,000 shares authorized as of March 31, 2022 and December 31, 2021; and no shares issued and outstanding as of March 31, 2022 and December 31, 2021
Common stock, $0.00001 par value, 300,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 58,010,823 shares issued and outstanding as of March 31, 2022 and December 31, 2021	1	1
Additional paid-in-capital	528,793	525,400
Accumulated other comprehensive loss	(309)
Accumulated deficit	(167,186)	(141,351)
Total stockholders’ equity	361,299	384,050
Total liabilities and stockholders’ equity	$ 378,606	$ 401,987